Trial Profile
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib With Trametinib in Chinese Subjects With Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 25 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 23 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2018.